Click the links below to find more information:

SOPH video/templatefiles/umc_video.aspx?id=2147548944Mannings for Health2016-04-25-01 $100 campaign for Children’s of Mississippi growth starts with $10 million gift from Sandersons
  • Research

    In addition to diagnostic imaging, we participate in clinical investigations to expand our body of knowledge specifically in the area of cardiovascular disease. Mississippi is currently in the epicenter of cardiovascular disease which includes heart disease, stroke and heart failure.

    UMMC participates in two large cardiovascular studies sponsored by the National Heart, Lung and Blood Institute - The Jackson Heart Study and the Atherosclerosis Risk in Communities Study (ARIC).

    We also provide consultation services for industry and principal investigators in early stage research development with design of the specified study endpoint(s), site selection, site initiation and quality assessment. Please contact the program director for more information regarding core laboratory services.

    PROMISE Trial

    The PROMISE study compares two different types of testing - functional and anatomic. These tests are being compared in order to determine which is more effective in diagnosing patients. This is done by studying the tests and their results to see which is more efficient in determining if patients have heart disease and require more testing and treatment. The objective is to determine whether an initial non-invasive anatomic imaging strategy with coronary CT angiography (CTA) will improve clinical outcomes in subjects with symptoms concerning for coronary artery disease relative to an initial functional testing strategy (usual care).

    RESCUE Trial

    The RESCUE trial is funded by a grant for comparative-effectiveness research from the Agency for Healthcare Research and Quality. This randomized, controlled, diagnostic, multicenter, phase III trial will assess two imaging technologies - coronary computed tomography angiography (CCTA) and single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) - in diagnosing cardiac disease in patients with stable angina or angina equivalent. Results from diagnostic imaging assessment will guide subsequent therapeutic approach.

    Participants with positive cardiac findings on diagnosis will be guided to optimal medical therapy (OMT) or diagnostic invasive coronary angiography (ICA) and possible revascularization, depending on extent and location of disease. Participants will be followed to collect healthcare utilization data, cardiac events, and quality-of-life questionnaires.

    MagnaSafe Registry

    The MagnaSafe Registry is a prospective multi-center study designed to determine the risks of performing non-thoracic 1.5T MRI scanning for patients with implanted pacemakers and Implantable Cardioverter-Defibrillators (ICDs). We will determine the rates of temporary and permanent device parameter changes, including changes in lead threshold, lead impedance and battery voltage. It is anticipated that the results of the registry will change the published guidelines for performing MRI in patients with implanted cardiac devices and provide physicians the risk-assessment data needed to assess the use of MRI as a diagnostic tool when no alternative diagnostic imaging technology is appropriate.

    Collaborative research projects